203.00
-2.00
(-0.98%)
Real-time:
11:15am BST
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | 203.00 - 205.00 |
| 52 week | 33.59 - 353.45 |
| Open | 203.00 |
| Vol / Avg. | 8,509.00/372.00 |
| Mkt cap | 95.44M* |
| P/E | - |
| Div/yield | - |
| EPS | -2.10* |
| Shares | 47.01M |
| Beta | - |
| Inst. own | - |
| *GBP |
Events
Jun 14, 2013
Silence Therapeutics plc Annual General Meeting
Apr 23, 2013
Silence Therapeutics PLC General Meeting
|
|
Key stats and ratios
| Q2 (Jun '12) | 2011 | |
| Net profit margin | -63583.79% | -827.12% |
| Operating margin | -63645.95% | -834.23% |
| EBITD margin | - | -722.23% |
| Return on average assets | -220.90% | -17.02% |
| Return on average equity | -233.20% | -17.80% |
| Employees | 37 | - |
| Carbon Disclosure Rating | - | - |
Address
The Royal Institution of Great Britain 21 Albemarle Street
LONDON, ENG W1S 4BS
United Kingdom - Map
+44-20-74916520 (Phone)
+44-20-74916521 (Fax)
LONDON, ENG W1S 4BS
United Kingdom - Map
+44-20-74916520 (Phone)
+44-20-74916521 (Fax)
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
Silence Therapeutics plc (Silence) is a biotechnology research and development company. Silence, along with its subsidiaries, is engaged in research and development of pharmaceutical products. The Company discovers, develops and delivers ribonucleic acid (RNA) interference (RNAi) therapeutics for the treatment of serious diseases. Silence operates two segments: RNAi therapeutics and Immunotherapy. The Company has two licence agreements with partner Quark Pharmaceuticals, for products PF 04523655 and QPI 1002, both of which are in development in two different therapeutic indications. The Company�s product pipeline includes PF 4523655 for diabetic macular edema, PF 4523655 for age related macular degeneration, QPI 1002 for prevention of delayed graft function, QPI 1002 for Acute Kidney Injury, Aut027 for Solid Tumours, and Atu111 for Acute Lung Injury.
Officers and directors
| Jerry A. P. Randall | Executive Chairman of the Board | |
| Tim Freeborn | Finance Director | |
| David Mack | Non-Executive Director |